{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:10:18Z","timestamp":1792696218323,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["11I5623N"],"award-info":[{"award-number":["11I5623N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01078-8","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T05:02:17Z","timestamp":1724821337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Nitazene test strips: a laboratory evaluation"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-8965","authenticated-orcid":false,"given":"Liam M.","family":"De Vrieze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-348X","authenticated-orcid":false,"given":"Christophe P.","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-441X","authenticated-orcid":false,"given":"Marthe M.","family":"Vandeputte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"1078_CR1","unstructured":"UNODC. Booklet 4 - Drug market trends of cocaine, amphetamine-type stimulants and new psychoactive substances [Internet]. World Drug Rep. 2022. 2022 [cited 2023 Jul 26]. https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2022.html"},{"key":"1078_CR2","unstructured":"EMCDDA. European drug report 2023: Trends and developments [Internet]. Luxembourg: Publications Office of the European Union. 2023. https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2023_en"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2215-0366(19)30218-4","volume":"6","author":"Y Bao","year":"2019","unstructured":"Bao Y, Meng S, Shi J, Lu L. Control of fentanyl-related substances in China. Lancet Psychiatry. 2019;6:e15.","journal-title":"Lancet Psychiatry"},{"key":"1078_CR4","unstructured":"UNODC. CND decision on international control of isotonitazene enters into force [Internet]. 2021 [cited 2023 Jul 28]. https:\/\/www.unodc.org\/LSS\/announcement\/Details\/65247392-26c7-4446-a2b6-270226103036"},{"key":"1078_CR5","unstructured":"117th Congress. H.R. 5305 - Extending government funding and delivering emergency assistance act. 2021."},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","volume":"12","author":"I Ujv\u00e1ry","year":"2021","unstructured":"Ujv\u00e1ry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, et al. DARK classics in chemical neuroscience: Etonitazene and related benzimidazoles. ACS Chem Neurosci. 2021;12:1072\u201392.","journal-title":"ACS Chem Neurosci"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","volume":"12","author":"MM Vandeputte","year":"2021","unstructured":"Vandeputte MM, Van Uytfanghe K, Layle NK, St. Germaine DM, Iula DM, Stove CP. Synthesis, chemical characterization, and \u00b5-opioid receptor activity assessment of the emerging group of nitazene 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci. 2021;12:1241\u201351.","journal-title":"ACS Chem Neurosci"},{"key":"1078_CR8","unstructured":"Krotulski AJ, Walton SE, Mohr ALA, Logan BK, Trend Q1 2024: NPS opioids in the United States [Internet]. 2024 [cited 2024 May 8]. https:\/\/www.cfsre.org\/images\/trendreports\/2024-Q1-NPS-Opioids-Trend-Report.pdf"},{"key":"1078_CR9","unstructured":"UNODC, February. 2024 \u2013 UNODC EWA: Nitazenes \u2013 a new group of synthetic opioids emerges [Internet]. 2024 [cited 2024 Jun 15]. https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/cbec8f4c-73aa-49ee-9e2b-75620af8a910"},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/dta.2738","volume":"12","author":"P Blanckaert","year":"2020","unstructured":"Blanckaert P, Cannaert A, Van Uytfanghe K, Hulpia F, Deconinck E, Van Calenbergh S, et al. Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. Drug Test Anal. 2020;12:422\u201330.","journal-title":"Drug Test Anal"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/jat\/bkab082","volume":"46","author":"MM Vandeputte","year":"2022","unstructured":"Vandeputte MM, Krotulski AJ, Papsun DM, Logan BK, Stove CP. The rise and fall of isotonitazene and brorphine: two recent stars in the synthetic opioid firmament. J Anal Toxicol. 2022;46:115\u201321.","journal-title":"J Anal Toxicol"},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"107121","DOI":"10.1016\/j.isci.2023.107121","volume":"26","author":"NJ Malcolm","year":"2023","unstructured":"Malcolm NJ, Palkovic B, Sprague DJ, Calkins MM, Lanham JK, Halberstadt AL, et al. Mu-opioid receptor selective superagonists produce prolonged respiratory depression. iScience. 2023;26:107121.","journal-title":"iScience"},{"key":"1078_CR13","doi-asserted-by":"crossref","unstructured":"De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ et al. In vitro structure\u2013activity relationships and forensic case series of emerging 2-benzylbenzimidazole \u2018nitazene\u2019 opioids. Arch Toxicol. 2024;98:2999\u20133018.","DOI":"10.1007\/s00204-024-03774-7"},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"109939","DOI":"10.1016\/j.drugalcdep.2023.109939","volume":"249","author":"MM Vandeputte","year":"2023","unstructured":"Vandeputte MM, Tsai M-HM, Chen L, Glatfelter GC, Walther D, Stove CP, et al. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. Drug Alcohol Depend. 2023;249:109939.","journal-title":"Drug Alcohol Depend"},{"key":"1078_CR15","doi-asserted-by":"crossref","unstructured":"Glatfelter GC, Vandeputte MM, Chen L, Walther D, Tsai M-HM, Shi L et al. Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u2018nitazene\u2019 opioids associated with human overdose. Psychopharmacology (Berl). 2023;240:2573\u201384.","DOI":"10.1007\/s00213-023-06451-2"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1093\/jat\/bkac062","volume":"47","author":"JL Schumann","year":"2023","unstructured":"Schumann JL, Syrjanen R, Alford K, Mashetty S, Castle JW, Rotella J, et al. Intoxications in an Australian emergency department involving \u2018nitazene\u2019 benzylbenzimidazole synthetic opioids (etodesnitazene, butonitazene and protonitazene). J Anal Toxicol. 2023;47:e6\u20139.","journal-title":"J Anal Toxicol"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/15563650.2024.2309321","volume":"62","author":"M Pucci","year":"2024","unstructured":"Pucci M, Singh Jutley G, Looms J, Ford L. N-desethyl isotonitazene detected in polydrug users admitted to hospital in Birmingham, United Kingdom. Clin Toxicol. 2024;62:19\u201325.","journal-title":"Clin Toxicol"},{"key":"1078_CR18","doi-asserted-by":"crossref","unstructured":"Killeen N, Lakes R, Webster M, Killoran S, McNamara S, Kavanagh P et al. The emergence of nitazenes on the Irish heroin market and national preparation for possible future outbreaks. Addiction. 2024;119:1657\u20138.","DOI":"10.1111\/add.16525"},{"key":"1078_CR19","doi-asserted-by":"publisher","unstructured":"Killoran S, McNamara S, Kavanagh P, O\u2019Brien J, Lakes R. Identification of N-pyrrolidino protonitazene in powders sold as heroin and associated with overdose clusters in Dublin and Cork, Ireland. Drug Test Anal. 2024. https:\/\/doi.org\/10.1002\/dta.3707","DOI":"10.1002\/dta.3707"},{"key":"1078_CR20","unstructured":"EMCDDA. European drug report 2024: Trends and developments [Internet]. Luxembourg: Publications Office of the European Union. 2024. https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024_en"},{"key":"1078_CR21","unstructured":"Health NSW. Heroin found to contain a potent opioid (\u2018nitazene\u2019) - Public drug warnings [Internet]. 2022 [cited 2024 Jun 15]. https:\/\/www.health.nsw.gov.au:443\/aod\/public-drug-alerts\/Pages\/heroin-found-to-contain-nitazenes.aspx"},{"key":"1078_CR22","unstructured":"High Alert NZ. Fake oxycodone tablets linked to serious harm [Internet]. 2023 [cited 2024 Jun 16]. https:\/\/www.highalert.org.nz\/alerts-and-notifications\/fake-oxycodone-tablets-linked-to-serious-harm\/"},{"key":"1078_CR23","unstructured":"Toronto\u2019s Drug Checking Service. N-desethyl etonitazene and protonitazepyne: New nitazene opioids circulating in Toronto\u2019s unregulated opioid supply [Internet]. 2024 [cited 2024 Jun 16]. https:\/\/drugchecking.community\/drug-information\/n-desethyl-etonitazene-and-protonitazepyne\/"},{"key":"1078_CR24","unstructured":"Victoria Department of Health. Protonitazene sold as ketamine [Internet]. State Government of Victoria, Australia; 2022 [cited 2024 Jun 16]. https:\/\/www.health.vic.gov.au\/drug-alerts\/yellow-powder-containing-protonitazene-may-be-sold-as-ketamine"},{"key":"1078_CR25","unstructured":"Victoria Department of Health. Metonitazene sold as cocaine [Internet]. State Government of Victoria, Australia; 2023 [cited 2024 Jun 16]. https:\/\/www.health.vic.gov.au\/drug-alerts\/metonitazene-mis-sold-as-cocaine"},{"key":"1078_CR26","unstructured":"NSW Health. Public health warning: tablets sold as MDMA (Ecstasy) found to contain a potent opioid - News [Internet]. 2024 [cited 2024 Jun 16]. https:\/\/www.health.nsw.gov.au:443\/news\/Pages\/20240129_00.aspx"},{"key":"1078_CR27","unstructured":"Cormac O\u2019Keeffe security correspondant. Alert as deadly opiate nitazene is found in fake sedative tablets [Internet]. Ir. Exam. 2024 [cited 2024 Jun 16]. https:\/\/www.irishexaminer.com\/news\/arid-41416816.html"},{"key":"1078_CR28","unstructured":"Campbell G. Highly potent synthetic opioid found in fake diazepam tablet, possible nationwide circulation [Internet]. N. Z. Her. 2024 [cited 2024 Jun 16]. https:\/\/www.nzherald.co.nz\/nz\/n-desethyletonitazene-found-in-fake-diazepam-tablet-in-wellington\/5FTDT57AYFEILGPOWOOLYZCI4E\/"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.fsir.2024.100375","volume":"10","author":"KR Gon\u00e7alves de Ara\u00fajo","year":"2024","unstructured":"Gon\u00e7alves de Ara\u00fajo KR, Fabris AL, Junior LFN, Soares AL, Costa JL, Yonamine M. Synthetic illicit opioids in Brazil: Nitazenes arrival. Forensic Sci Int Rep. 2024;10:100375.","journal-title":"Forensic Sci Int Rep"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139.","journal-title":"Int J Drug Policy"},{"key":"1078_CR31","doi-asserted-by":"crossref","unstructured":"Kutscher E, Barber Grossi M, LaPolla F, Lee JD. Fentanyl test Strips for harm reduction: A scoping review. J Addict Med. 2024;18.","DOI":"10.1097\/ADM.0000000000001321"},{"key":"1078_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122\u20138.","journal-title":"Int J Drug Policy"},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"103147","DOI":"10.1016\/j.drugpo.2021.103147","volume":"92","author":"MK Reed","year":"2021","unstructured":"Reed MK, Roth AM, Tabb LP, Groves AK, Lankenau SE. I probably got a minute: perceptions of fentanyl test strip use among people who use stimulants. Int J Drug Policy. 2021;92:103147.","journal-title":"Int J Drug Policy"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"103643","DOI":"10.1016\/j.drugpo.2022.103643","volume":"103","author":"MK Reed","year":"2022","unstructured":"Reed MK, Guth A, Salcedo VJ, Hom JK, Rising KL. You can\u2019t go wrong being safe: motivations, patterns, and context surrounding use of fentanyl test strips for heroin and other drugs. Int J Drug Policy. 2022;103:103643.","journal-title":"Int J Drug Policy"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/10826084.2023.2275561","volume":"59","author":"MK Reed","year":"2024","unstructured":"Reed MK, Siegler A, Esteves Camacho T, London K, Schaeffer K, Rising KL. Making harm reduction more accessible: fentanyl test strip awareness and attitudes among emergency department patients who use drugs. Subst Use Misuse. 2024;59:398\u2013404.","journal-title":"Subst Use Misuse"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"103741","DOI":"10.1016\/j.drugpo.2022.103741","volume":"106","author":"S Klaire","year":"2022","unstructured":"Klaire S, Janssen RM, Olson K, Bridgeman J, Korol EE, Chu T, et al. Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada. Int J Drug Policy. 2022;106:103741.","journal-title":"Int J Drug Policy"},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12954-023-00767-0","volume":"20","author":"AS Tilhou","year":"2023","unstructured":"Tilhou AS, Zaborek J, Baltes A, Salisbury-Afshar E, Malicki J, Brown R. Differences in drug use behaviors that impact overdose risk among individuals who do and do not use fentanyl test strips for drug checking. Harm Reduct J. 2023;20:41.","journal-title":"Harm Reduct J"},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"109610","DOI":"10.1016\/j.drugalcdep.2022.109610","volume":"240","author":"JN Park","year":"2022","unstructured":"Park JN, Sherman SG, Sigmund V, Breaud A, Martin K, Clarke WA. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples. Drug Alcohol Depend. 2022;240:109610.","journal-title":"Drug Alcohol Depend"},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12954-023-00921-8","volume":"21","author":"JC Halifax","year":"2024","unstructured":"Halifax JC, Lim L, Ciccarone D, Lynch KL. Testing the test strips: laboratory performance of fentanyl test strips. Harm Reduct J. 2024;21:14.","journal-title":"Harm Reduct J"},{"key":"1078_CR40","unstructured":"BTNX Inc. BTNX Rapid Respone nitazene test strip product insert [Internet]. 2023. https:\/\/strategicstrike.blob.core.windows.net\/lochness-products\/resources\/NTZ-18S26-100%20(EN)%20Instructions-Product%20Insert-180.pdf"},{"key":"1078_CR41","unstructured":"BTNX Inc. BTNX Rapid Reponse nitazene white paper [Internet]. 2024. https:\/\/cloudfront.exchangesupplies.org\/pdfs\/BTNX%20Rapid%20Response%20Nitazene%20White%20Paper%202024-03%20V3%201%20(1).pdf"},{"key":"1078_CR42","doi-asserted-by":"crossref","unstructured":"Sisco E, Appley MG, Pyfrom EM, Banta-Green CJ, Shover CL, Molina CA et al. Beyond fentanyl test strips: investigating other urine drug test strips for drug checking applications. Forensic Chem. 2024;40:100594.","DOI":"10.1016\/j.forc.2024.100594"},{"key":"1078_CR43","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/dta.3113","volume":"13","author":"P Blanckaert","year":"2021","unstructured":"Blanckaert P, Balcaen M, Vanhee C, Risseeuw M, Canfyn M, Desmedt B, et al. Analytical characterization of etonitazepyne, a new pyrrolidinyl-containing 2-benzylbenzimidazole opioid sold online. Drug Test Anal. 2021;13:1627\u201334.","journal-title":"Drug Test Anal"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.drugpo.2020.102661","volume":"77","author":"TC Green","year":"2020","unstructured":"Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661.","journal-title":"Int J Drug Policy"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"104102","DOI":"10.1016\/j.drugpo.2023.104102","volume":"118","author":"C Norman","year":"2023","unstructured":"Norman C, Marland V, McKenzie C, M\u00e9nard H. Nic Da\u00e9id N. Evaluation of fentanyl immunoassay test strips for rapid in-situ detection of fentanyl and fentanyl analogs in seized samples and alternative matrices. Int J Drug Policy. 2023;118:104102.","journal-title":"Int J Drug Policy"},{"key":"1078_CR46","doi-asserted-by":"publisher","unstructured":"Sisco E, Nestadt DF, Bloom MB, Schneider KE, Elkasabany RA, Rouhani S et al. Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications. Drug Test Anal. 2023. https:\/\/doi.org\/10.1002\/dta.3612","DOI":"10.1002\/dta.3612"},{"key":"1078_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1373\/clinchem.2015.241315","volume":"62","author":"KL Thoren","year":"2016","unstructured":"Thoren KL, Colby JM, Shugarts SB, Wu AHB, Lynch KL. Comparison of Information-Dependent Acquisition on a Tandem Quadrupole TOF vs a Triple Quadrupole Linear Ion Trap Mass Spectrometer for Broad-Spectrum Drug Screening. Clin Chem. 2016;62:170\u20138.","journal-title":"Clin Chem"},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/jat\/bkz030","volume":"43","author":"M Mardal","year":"2019","unstructured":"Mardal M, Andreasen MF, Mollerup CB, Stockham P, Telving R, Thomaidis NS, et al. HighResNPS.com: an online crowd-sourced HR-MS database for suspect and non-targeted screening of New Psychoactive substances. J Anal Toxicol. 2019;43:520\u20137.","journal-title":"J Anal Toxicol"},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12954-024-01044-4","volume":"21","author":"A Timmerman","year":"2024","unstructured":"Timmerman A, Balcaen M, Coopman V, Degreef M, Pottie E, Stove CP. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials. Harm Reduct J. 2024;21:127.","journal-title":"Harm Reduct J"},{"key":"1078_CR50","unstructured":"Hughes E. How to use nitazene test strips [Internet]. The Level. 2024 [cited 2024 Jun 28]. https:\/\/thelevel.org.nz\/news-and-stories\/how-to-use-nitazene-test-strips"},{"key":"1078_CR51","volume-title":"Evaluation of xylazine test strips (BTNX) for drug checking purposes","author":"A Krotulski","year":"2023","unstructured":"Krotulski A, Shinefeld J, DeBord J, Teixeira da Silva D, Logan B. Evaluation of xylazine test strips (BTNX) for drug checking purposes. United States: Center for Forensic Science Research and Education; 2023."},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12954-023-00911-w","volume":"20","author":"KL Hayes","year":"2023","unstructured":"Hayes KL, Lieberman M. Assessment of two brands of fentanyl test strips with 251 synthetic opioids reveals blind spots in detection capabilities. Harm Reduct J. 2023;20:175.","journal-title":"Harm Reduct J"},{"key":"1078_CR53","unstructured":"ANSM. D\u00e9cision du 05\/07\/2024 portant modification de la liste des substances class\u00e9es comme stup\u00e9fiants [Internet]. 2024 [cited 2024 Jul 10]. https:\/\/ansm.sante.fr\/actualites\/decision-du-05-07-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"key":"1078_CR54","unstructured":"Bundesministerium f\u00fcr Gesundheit. Das Neue-psychoaktive-Stoffe-Gesetz (NPSG) [Internet]. [cited 2024 Jul 10]. https:\/\/www.bundesgesundheitsministerium.de\/service\/begriffe-von-a-z\/n\/npsg"},{"key":"1078_CR55","unstructured":"Helse- og omsorgsdepartementet. Forskrift om narkotika (narkotikaforskriften) [Internet]. [cited 2024 Jul 10]. https:\/\/lovdata.no\/dokument\/SF\/forskrift\/2013-02-14-199\/KAPITTEL_1#KAPITTEL_1"},{"key":"1078_CR56","unstructured":"Eidgen\u00f6ssisches Departement des Innern. Verordnung des EDI \u00fcber die Verzeichnisse der Bet\u00e4ubungsmittel, psychotropen Stoffe, Vorl\u00e4uferstoffe und Hilfschemikalien (Bet\u00e4ubungsmittelverzeichnisverordnung, BetmVV-EDI) [Internet]. [cited 2024 Jul 10]. https:\/\/www.fedlex.admin.ch\/eli\/oc\/2023\/569\/de"},{"key":"1078_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12954-021-00478-4","volume":"18","author":"T-LE Lockwood","year":"2021","unstructured":"Lockwood T-LE, Vervoordt A, Lieberman M. High concentrations of illicit stimulants and cutting agents cause false positives on fentanyl test strips. Harm Reduct J. 2021;18:30.","journal-title":"Harm Reduct J"},{"key":"1078_CR58","unstructured":"EMCDDA. European Database on New Drugs (EDND) (restricted access) [Internet]. [cited 2024 May 15]. https:\/\/ednd2.emcdda.europa.eu\/ednd\/login"},{"key":"1078_CR59","unstructured":"Krotulski AJ, Walton SE, Mohr ALA, Logan BK, Trend Q1 2021: NPS opioids in the United States [Internet]. 2021 [cited 2024 Jul 30]. https:\/\/www.cfsre.org\/images\/trendreports\/2021-Q1_NPS-Opioids_Trend-Report.pdf"},{"key":"1078_CR60","unstructured":"Krotulski AJ, Walton SE, Mohr ALA, Logan BK, Trend Q3 2021: NPS opioids in the United States [Internet]. 2021 [cited 2024 Jul 30]. https:\/\/www.cfsre.org\/images\/trendreports\/2021-Q3-NPS-Opioids-Trend-Report.pdf"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01078-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T05:06:12Z","timestamp":1724821572000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01078-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01078-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"159"}}